TVRD 10-Q filed 2026-11-13 | Key takeaways
TVRD filed its 10-Q; the most relevant disclosure change is expanded At-the-market equity offerings: During Q3 2026, the company sold 3,110,769 shares of common stock for $11.0 million under the Original Sales Agreement Prospectus and 853,843 shares for $2.3 million under the New Sales Agreement Prospectus Supplement, with total commissions and offering expen. Customer concentration: Vendor A represented 44% of operating_expenses; Vendor A represented 66% of accounts_payable.
Key takeaways
Financial results: Q3 2026 net loss of $6.1 million versus $5.5 million in Q3 2025; nine-month net loss of $19.4 million versus $10.9 million in prior year period.
ATM equity offerings: Sold 3.1 million shares for $11.0 million under Original Sales Agreement Prospectus and 853,843 shares for $2.3 million under New Sales Agreement Prospectus Supplement during Q3 2026; $7.4 million remains available.
Cash position: Cash and cash equivalents increased to $22.3 million as of September 30, 2026 from $15.8 million at June 30, 2026, primarily due to ATM sales.
Going concern: Management concluded that present capital resources will not be sufficient to fund planned operations for at least one year from the financial statement issuance date.
Material weaknesses in ICFR: Identified weaknesses related to insufficient finance personnel, lack of formalized risk assessment, inadequate review of financial statements and R&D expenses, and lack of formal monitoring activities.
Clinical pipeline update: TTI-101 HCC Phase 1b/2 topline data expected early Q1 2027; TTI-109 selected ulcerative colitis as initial indication following July 2026 Phase 1 results showing up to 60% reduction in STAT3-driven immune cell populations.
Supplier concentration: Vendor A represented 44% of Q3 2026 operating expenses versus 35% in Q3 2025, and 66% of accounts payable as of September 30, 2026 versus 84% as of December 31, 2025.
Key metrics
Customer concentration
Disclosure changes
- At-the-market equity offerings
During Q3 2026, the company sold 3,110,769 shares of common stock for $11.0 million under the Original Sales Agreement Prospectus and 853,843 shares for $2.3 million under the New Sales Agreement Prospectus Supplement, with total commissions and offering expenses of $0.5 million. Approximately $7.4 million remained available for future sales as of September 30, 2026.
The ATM facility is the company's primary source of funding given its going concern status and lack of product revenue. - Internal control over financial reporting - material weaknesses
The company identified material weaknesses including: (a) lack of sufficient finance/accounting personnel, (b) lack of formalized risk assessment process, (c) inadequate review of financial statements and disclosures, (d) inadequate review of prepaid and accrued R&D expenses related to CRO, and (e) lack of formal monitoring activities. Remediation efforts include hiring additional experienced accounting personnel, formalizing risk assessment, and implementing monitoring programs.
Material weaknesses in ICFR increase the risk of material misstatement in financial statements and may require significant remediation costs. - License agreements - BCM Second Agreement termination
The company terminated the BCM Second Agreement in April 2026, effective immediately, related to STAT3 inhibitors in anaphylaxis conditions. The company determined this termination was not material.
The termination reduces future potential milestone and royalty obligations, though the indication was not part of the company's core development focus. - Common stock outstanding increase
Common stock outstanding increased from 9,381,344 shares at December 31, 2025 to 13,345,956 shares at September 30, 2026, an increase of approximately 42%, due to ATM stock sales.
Significant dilution to existing shareholders from ATM offerings to fund operations. - Legal proceedings
A lawsuit filed by Shaheen Wirk, Palkon Holdings LLC, and Palkon TT Holdings LLC in March 2026 alleging breach of Registration Rights Agreement was dismissed on October 7, 2026; plaintiffs filed a motion to reargue on November 6, 2026.
Litigation outcome could impact the company's ability to raise capital through equity offerings if registration rights are disputed. - Research and development expenses - TTI-101 HCC
TTI-101 HCC expenses were $2.4 million in Q3 2026 versus $0.6 million in Q3 2025, an increase of $1.8 million (307%), due to changes in total trial costs resulting from trial scope changes. Nine-month HCC expenses were $4.2 million versus $2.0 million in prior year period.
The significant increase in HCC trial costs reflects expanded clinical trial scope and activities.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow TVRD in real time
Get material earnings, filing, IR, and earnings-call alerts by email.